Biochips Market to Grow from USD 14.01 Billion in 2025 to USD 21.36 Billion by 2030, at a CAGR of 8.8% - MarketsandMarkets™
Delray Beach, FL , Aug. 18, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global biochips market to reach USD 21.36 billion by 2030 from USD 14.01 billion in 2025, growing at a CAGR of 8.8% during the forecast period. Market growth is driven by increasing demand for personalized medicine and the rising focus on precision diagnostics. The growing prevalence of chronic and infectious diseases, expanding applications in drug discovery, genomics, and proteomics, and increasing emphasis on non-invasive diagnostic techniques such as liquid biopsy are supporting broader adoption of biochip technologies.
Get PDF Brochure - Market Data & Segmentation:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=54
Key Market Highlights
Why This Market Matters
Biochips are gaining importance as healthcare and life sciences organizations seek high-throughput, precise, and efficient approaches to biological analysis. Growing demand for personalized medicine and precision diagnostics is increasing the use of biochip technologies across genomics, proteomics, drug discovery, and clinical applications. The rising prevalence of chronic and infectious diseases, combined with the growing need for non-invasive diagnostics and point-of-care testing, is further supporting market expansion.
Market Overview
The biochips market is expanding as advanced bioanalytical technologies become increasingly integrated into clinical research and healthcare workflows. High-throughput screening requirements across clinical and research settings are supporting adoption, while the integration of AI, machine learning, and microfluidics is enabling product innovation and improved efficiency. Research collaborations between academia and industry, along with increasing penetration of e-commerce distribution channels, are also enhancing access to biochip technologies, particularly in emerging markets.
Analyst Perspective
The biochips industry is moving toward more integrated, high-throughput, and data-driven analytical workflows. The convergence of biochip platforms with AI, machine learning, microfluidics, genomics, and advanced bioinformatics is creating opportunities for more efficient biological analysis and precision healthcare applications. Companies that strengthen their product portfolios through new product introductions, strategic partnerships, and expansion into emerging markets are expected to improve their competitive positioning.
Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=54
Segment Analysis
The biochips market is supported by expanding applications across personalized medicine, precision diagnostics, drug discovery, genomics, and proteomics. The growing need for high-throughput screening in clinical and research settings is increasing demand for technologies that can process biological information efficiently and accurately.
The market is also benefiting from the increasing emphasis on non-invasive diagnostic techniques, including liquid biopsy, and the rising demand for point-of-care diagnostics. These applications are broadening the role of biochip technologies beyond research environments and into clinical and decentralized testing settings.
Regional Analysis
The attached Article 1 identifies expanding adoption in emerging markets, supported by research collaborations between academia and industry and increasing penetration of e-commerce distribution channels. These factors are improving accessibility to biochip technologies and supporting market adoption. The provided source materials do not specify a single largest regional market or a regional CAGR, so no unsupported regional ranking is included in this release.
Key Industry Trends
Competitive Landscape
The competitive landscape of the biochips market is led by established global companies including Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), and QIAGEN (Germany), among other market participants. These companies are pursuing organic and inorganic growth strategies, including new product introductions, strategic partnerships, and expansion into emerging markets.
Thermo Fisher Scientific Inc. is advancing its position by enhancing microarray technologies and bioinformatics solutions supporting genomics, diagnostics, and drug discovery. Its broader portfolio includes scientific instrumentation, reagents, consumables, software, and services across healthcare, life sciences, academia, government, and biotechnology.
Illumina, Inc. is a leading genomics and life sciences company with integrated systems for analyzing genetic variation and biological function. Its portfolio includes next-generation sequencing instruments, array-based genotyping systems, library preparation kits, sequencing reagents, consumables, and software and analytics solutions. Its technologies support applications including oncology, reproductive health, infectious disease, agriculture, and population genomics.
Agilent Technologies, Inc. is expanding its offerings in genomic profiling and molecular diagnostics, with a focus on cancer diagnostics and precision medicine through advanced analytical tools. F. Hoffmann-La Roche Ltd is strengthening its molecular diagnostics portfolio, particularly in oncology and genetic testing technologies, while QIAGEN focuses on molecular testing and genetic analysis to support precision medicine and oncology diagnostics.
Related Reports
Next-generation Sequencing Market
Genomics Market